Opinion

Video

Treatment Considerations for Patients With HER2+ NSCLC

Key Takeaways

  • Clinicians must balance therapeutic benefits and risks, particularly concerning adverse events like interstitial lung disease, by tailoring treatment plans to individual patient needs.
  • Evolving strategies to address resistance to HER2-directed therapies focus on understanding resistance mechanisms and developing novel agents or combination therapies.
SHOW MORE

Panelists discuss how clinicians carefully weigh the efficacy of HER2-directed therapies against their safety profiles, particularly focusing on managing serious adverse events like interstitial lung disease, while also considering emerging strategies to combat resistance to these treatments as research in the field progresses.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
2 experts in this video
2 experts in this video
Dr Sundar Jagannath
1 expert in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo